REMARKS/ARGUMENTS

After entry of the amendment, Claims 1-28 remain in this application. Claims 1, 10, 13, 16, 18 and 19 have been amended. Claims 15-28 have been withdrawn.

The Examiner has restricted prosecution of this application to one of forty groups of claims. Applicants elect Group I (Claims 1-11) without traverse. The pending claims have been amended to recite the compound of Formula I wherein X is H, cyano, halogen, haloalkyl, NO, NO₂, NO₃, phosphonates, PR¹⁵R¹⁶R¹⁷, NH₂, NR¹⁵R¹⁶, OH, OR¹⁵, SR¹⁵, SCN, N₃, OC(O)R¹⁵, C(O)₂R¹⁵, OC(O)NR¹⁵R¹⁶, C(O)₂NR¹⁵R¹⁶, C(O)NR¹⁵R¹⁶, P(O)₂OR¹⁵, S(O)₂R¹⁵, alkyl, alkenyl, alkynyl, aryl, aralkyl, alkaryl, heteroalkyl, heterocycle, heteroaryl, or alkylhereoalyl and T is a therapeutic agent. Applicants also elect Group XI (Claims 12-14), the composition claims that correlate with the elected group.

The Examiner has also required an election of species. Applicants elect the species of the compound of Formula I wherein X is H, and more specifically the compound described in Example 19:

Wherein X is H and R is:

Page 14 of 15

Appl. No. 10/027,593

Amendment Dated August 30, 2004

Reply to Restriction Requirement of June 29, 2004

Applicants note that the Examiner has stated that if the Applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims of Group XXI (Claims 15-28) that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04.

The Commissioner is authorized to charge any fees or credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

KING & SPALDING LLP

By: Madelus of

Madeline I. Johnston, Ph.D., Esq.

Reg. No. 36,174

191 Peachtree Street, 45th Floor Atlanta, Georgia 30303-1763

Tel.: (404) 572-3541